eClinicalMedicine, Volume 48, June 2022
Background: Abatacept is a selective T-cell costimulation modulator approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, and psoriatic arthritis. Reports were recently published on hepatitis B virus reactivation (HBVr) in patients who were treated with abatacept. However, the literature is limited to case reports and series, and no study has investigated the relationship between HBVr and abatacept using extensive population-based databases.
The Lancet Planetary Health, Volume 6, June 2022
The Lancet Public Health, Volume 7, June 2022
The Lancet Regional Health - Americas, Volume 10, June 2022